Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PA 317

Next Previous
Drug Profile

PA 317

Alternative Names: Anti-CD7 chimeric antigen receptor T- cell therapy - PersonGen Biomedicine; Autologous CD7-CAR-T cells - PersonGen Biotherapeutics; CD7-CAR-T cells - PersonGen Biotherapeutics; PA3-17

Latest Information Update: 24 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PersonGen Biotherapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor T-cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II T-cell lymphoma
  • Phase I Precursor T-cell lymphoblastic leukaemia-lymphoma
  • No development reported Lymphoid leukaemia

Most Recent Events

  • 24 Jun 2025 Efficacy data from a phase-I trial in Precursor B-cell lymphoblastic leukaemia-lymphoma released by PersonGen Biotherapeutics
  • 16 May 2025 PA 317 is still in phase-I clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (In adolescents, In adults, In children, In the elderly, Second-line therapy or greater) in China (Parenteral) (NCT04004637)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Lymphoid-leukaemia(In adults) in China (Injection, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top